Notice of Application - 2005
FR Doc 05-4226 [Federal Register: March 4, 2005 (Volume 70, Number 42)] [Notices] [Page 10683] From the Federal Register Online via GPO Access [wais.access.gpo.gov] [DOCID:fr04mr05-120]
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to 21 CFR 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this is notice that on December 21, 2004, Sigma Aldrich Research Biochemicals, Inc., 1-3 Strathmore Road, Natick, Massachusetts 01760, made application by letter to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the basic classes of controlled substances listed in Schedules I and II:
| Drug |
Schedule |
| Cathinone (1235) |
I |
| Methcathinone (1237) |
I |
| Aminorex (1585) |
I |
| Alpha-ethyltryptamine (7249) |
I |
| Lysergic acid diethylamide (7315) |
I |
| Tetrahydrocannabinols (7370) |
I |
| 4-Bromo-2,5-dimethoxy-amphetamine (7391) |
I |
| 4-Bromo-2,5-dimethoxyphenethylamine (7392) |
I |
| 2,5-Dimethoxyamphetamine (7396) |
I |
| 3,4-Methylenedioxyamphetamine (7400) |
I |
| N-Hydroxy-3,4-methylenedioxyamphetamine |
I |
| (7402). 3,4-Methylenedioxy-N-ethylamphetamine (7404) |
I |
| 3,4-Methylenedioxymethamphetamine (MDMA) (7405) |
I |
| 1-[1-(2-Thienyl)cyclohexyl]piperidine (TCP) (7470) |
I |
| Heroin (9200) |
I |
| Normorphine (9313) |
I |
| Amphetamine (1100) |
II |
| Methamphetamine (1105) |
II |
| 1-Phenylcyclohexylamine (7460) |
II |
| Phencyclidine (7471) |
II |
| Cocaine (9041) |
II |
| Codeine (9050) |
II |
| Diprenorphine (9058) |
II |
| Ecgonine (9180) |
II |
| Levomethorphan (9210) |
II |
| Levorphanol (9220)I |
II |
| Meperidine (9230) |
II |
| Metazocine (9240) |
II |
| Methadone (9250) |
II |
| Morphine (9300) |
II |
| Thebaine (9333) |
II |
| Levo-alphacetylmethadol (9648)I |
II |
| Carfentanil (9743)I |
II |
| Fentanyl (9801) |
II |
The company plans to manufacture the listed controlled substances in bulk for laboratory reference standards.
Any other such applicant and any person who is presently registered with DEA to manufacture such a substance may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).
Any such written comments or objections being sent via regular mail may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537, Attention: DEA Federal Register Representative, Liaison and Policy Section (ODL); or any being sent via express mail should be sent to DEA Headquarters, Attention: DEA Federal Register Representative/ODL, 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must be filed no later than May 3, 2005.
Dated: February 23, 2005.
William J. Walker,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.
[FR Doc. 05-4226 Filed 3-3-05; 8:45 am]
BILLING CODE 4410-09-P
NOTICE: This is an unofficial version. An official version of this publication may be obtained
directly from the Government Printing Office (GPO).
|
